The Immunomodulation Lab
Our group investigates the interplay between immune cells and various disease including cancer and inflammation in vivo. Our aim is to understand the mechanism that control immunity and to identify novel targets for cancer immunotherapy.
We focussing on (1) CAR t-cells and (2) neutrophile extracellular traps (NETs).
Pediatric Tumors are particularly immunogenic. We develop and implement cutting-edge CAR t-cell technologies to control or eliminate cancer and to modulate the immune system. In our lab we combine and into novel therapeutic strategies which will ultimately benefit children suffering from cancer or immune disease.
​
NETs confer protection against infections, but also drive inflammation and immunopathology.
The Team
Michael Boettcher
Lab Director
Innate Immunity and CAR t-cells: NETs, Immunomodulation, Visulalisation, personalized Immunotherapy
Julia Elrod
Senior Researcher
Innate Immunity: NETs, transplantation, burns, wound healing, microcirculation
Michaela Klinke
Researcher
Innate Immunity: NETs, adhesion formation, bariatric surgery, CDH
Marina Niklaus
Researcher
Pediatric solid tumors: innate immunity and metastasis
​
Starting 2022
Tina Trautmann
Researcher
Pediatric solid tumors: CAR t-cells, immunity, microbioma
Martin Herrmann
Senior Advisor
Professor Martin Herrmann is Head of the Immunology Lab at Erlangen University.
Innate Immunity: neutrophils, neutrophil extracellular traps
Patrick Schlegel
Senior Advisor
Professor Patrick Schlegel is Head of Cellular Cancer Therapeutics at the Children's Hospital Westmead, University Sydney
​
Pediatric solid tumors: next generation CAR-T design